8-K: Bright Green Corporation Enters Restructuring Support Agreement, Plans Chapter 11 Filing

Bright Green Corporation has entered into a Restructuring Support Agreement with its major shareholder and plans to file for Chapter 11 bankruptcy to reorganize the company.

Summary

• Bright Green Corporation has entered into a Restructuring Support Agreement (RSA) with Lynn Stockwell, its major shareholder, founder, and sole officer and director.
• The RSA outlines the terms for a prepackaged Chapter 11 Plan of Reorganization.
• The Plan Sponsor has supported the Company financially and on numerous occasions over the last 4 years and currently has a pre-petition secured note (the Note) in an amount totaling not less than $2,825,000.
• The plan includes funding of a $5.4 million Exit Facility by the Plan Sponsor for working capital.
• The company anticipates needing a $300,000 DIP Facility.
• The plan involves repaying general unsecured claims with 20% cash and 80% new common stock.
• Existing common stockholders will receive new common stock after a 50-1 reverse stock split.
• The company plans to change its name to Drugs Made In America Corp.
• The Plan Sponsor will assume the role of CEO and Executive Chair for a two-year period.
• The company anticipates filing a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Florida in the coming days.
• The company expects its operations to continue as normal throughout the contemplated Court-supervised process.
• The company plans to emerge with federal loan guarantees for its 60 new mega farm owner/operators, that collectively will invest $3.5 billion to supply and strengthen the Drugs Made in America supply Chain.

Sentiment

Score: 3

Explanation: The sentiment is low due to the Chapter 11 filing, indicating significant financial distress. While there are some positive aspects, such as the Exit Facility and the potential for future growth, the overall outlook is negative.

Positives

• The Restructuring Support Agreement provides a framework for the company to address its financial challenges.
• The $5.4 million Exit Facility from the Plan Sponsor will provide working capital.
• The plan aims to repay general unsecured creditors, albeit partially.
• The company anticipates filing a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Florida in the coming days.
• The company expects its operations to continue as normal throughout the contemplated Court-supervised process.
• The company plans to emerge with federal loan guarantees for its 60 new mega farm owner/operators, that collectively will invest $3.5 billion to supply and strengthen the Drugs Made in America supply Chain.

Negatives

• The company is entering Chapter 11 bankruptcy, indicating significant financial distress.
• Existing common stockholders will experience dilution due to the issuance of new common stock to creditors.
• Trading in the company's securities during the Chapter 11 case is highly speculative and poses substantial risks.
• The company was compromised financially when globalization policies were not favorable for research, production and manufacturing within the United States.
• The past immigration policy made funding from the company's EB-5 program for investment capital impossible.

Risks

• Trading in the company's securities during the Chapter 11 case is highly speculative.
• The effectiveness of the Plan is subject to numerous conditions, including approval by the Bankruptcy Court.
• The company's ability to implement the Plan and raise funds under the EB-5 program is uncertain.
• The impact of new officers, directors, and employees on the company's business is uncertain.
• The company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors.

Future Outlook

The company anticipates filing a voluntary petition for reorganization under Chapter 11 and expects operations to continue as normal throughout the process. Upon emergence, the company anticipates changing its name to Drugs Made in America Corp. and implementing its owner/operator plan for a $3.5 billion investment.

Management Comments

• Lynn Stockwell stated that Bright Green Corporation was in a unique position to produce legal controlled substances but was compromised financially due to globalization policies and immigration policy.
• Lynn Stockwell looks forward to the new administration's promise to onboard the production and manufacturing of both the API and prescription drugs back to the United States creating an opportunity for this well positioned company and importantly rationalizing regulation for drugs made in America.

Industry Context

The company's restructuring plan is tied to the broader trend of reshoring drug production and manufacturing to the United States, driven by changes in globalization policies and immigration policy. The company aims to capitalize on this trend by establishing a network of DEA and FDA compliant mega farms for the production of controlled substances.

Comparison to Industry Standards

• It is difficult to compare Bright Green Corporation's situation directly to industry standards due to its unique focus on controlled substance production and its reliance on the EB-5 program.
• However, the company's restructuring plan shares similarities with other companies in distressed situations, such as seeking debtor-in-possession financing and negotiating with creditors.
• The company's plan to establish a network of mega farms is ambitious and would require significant capital investment and regulatory approvals.
• The company plans to emerge with federal loan guarantees for its 60 new mega farm owner/operators, that collectively will invest $3.5 billion to supply and strengthen the Drugs Made in America supply Chain.

Management Changes

Related Party Transactions

• The Restructuring Support Agreement with Lynn Stockwell, the company's major shareholder, founder, and sole officer and director, constitutes a related party transaction.
• The Plan Sponsor has supported the Company financially and on numerous occasions over the last 4 years and currently has a pre-petition secured note (the Note) in an amount totaling not less than $2,825,000.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new common stock to creditors and a reverse stock split.
• General unsecured creditors will receive partial repayment of their claims.
• Employees may be affected by the restructuring process.
• The company's suppliers and customers may experience disruptions during the Chapter 11 case.

Next Steps

• File a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Florida.
• Solicit votes on the Plan from holders of general unsecured claims.
• Obtain approval of the Plan from the Bankruptcy Court.
• Implement the terms of the Plan, including the Exit Facility, repayment of creditors, and reverse stock split.
• Change the company's name to Drugs Made In America Corp.
• Organize and strengthen the operations with a joint venture with at least one federal agency to undertake the research of all plant based controlled substances at its Grants, New Mexico facility on a cost-plus basis.
• Engage by contract with 60 participant franchisees to build, own and manage their own facilities capable of meeting the demand of plant based controlled substances API active pharmaceutical ingredients under the company's authorization.

Key Dates